Fulvestrantのソースを表示
←
Fulvestrant
ナビゲーションに移動
検索に移動
あなたには「このページの編集」を行う権限がありません。理由は以下の通りです:
この操作は、次のグループに属する利用者のみが実行できます:
登録利用者
。
このページのソースの閲覧やコピーができます。
{{Short description|Hormonal antineoplastic drug}} {{Use dmy dates|date=May 2024}} {{cs1 config |name-list-style=vanc |display-authors=6}} {{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 410130476 | image = Fulvestrant.svg | width = 250 | alt = <!-- Clinical data --> | pronounce = {{IPAc-en|f|ʊ|l|ˈ|v|ɛ|s|t|ɹ|ə|n|t}}<br />{{respell|fuul|VES|trənt}} | tradename = Faslodex, others | Drugs.com = {{drugs.com|monograph|fulvestrant}} | MedlinePlus = a607031 | DailyMedID = Fulvestrant | pregnancy_AU = D | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = [[Intramuscular injection]] | class = [[Antiestrogen]] | ATC_prefix = L02 | ATC_suffix = BA03 | ATC_supplemental = <!-- Legal status --> | legal_AU = S4 | legal_AU_comment = | legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F --> | legal_BR_comment = | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_CA_comment = | legal_DE = <!-- Anlage I, II, III or Unscheduled --> | legal_DE_comment = | legal_NZ = <!-- Class A, B, C --> | legal_NZ_comment = | legal_UK = POM | legal_UK_comment = <ref name=UKlabel2016 /> | legal_US = Rx-only | legal_US_comment = <ref name="Faslodex FDA label">{{cite web | title=Faslodex- fulvestrant injection | website=DailyMed | date=25 September 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83d7a440-e904-4e36-afb5-cb02b1c919f7 | access-date=24 May 2024 | archive-date=11 December 2023 | archive-url=https://web.archive.org/web/20231211231649/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83d7a440-e904-4e36-afb5-cb02b1c919f7 | url-status=live }}</ref> | legal_EU = Rx-only | legal_EU_comment = <ref>{{cite web | title=Faslodex | website=[[European Medicines Agency]] (EMA) | date=10 March 2004 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/faslodex | access-date=24 May 2024 | archive-date=19 October 2021 | archive-url=https://web.archive.org/web/20211019022354/https://www.ema.europa.eu/en/medicines/human/EPAR/faslodex | url-status=live }}</ref> | legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> | legal_UN_comment = | legal_status = Rx-only <!-- Pharmacokinetic data --> | bioavailability = Low<ref name="Dörwald2013" /> | protein_bound = 99%<ref name="Dörwald2013" /> | metabolism = [[Hydroxylation]], [[conjugation (biochemistry)|conjugation]] ([[glucuronidation]], [[sulfation]])<ref name="Dörwald2013" /> | metabolites = | onset = | elimination_half-life = {{abbrlink|IM|Intramuscular injection}}: 40–50 days<ref name="Dörwald2013">{{cite book |first=Florencio Zaragoza |last=Dörwald |title=Lead Optimization for Medicinal Chemists: Pharmacokinetic Properties of Functional Groups and Organic Compounds |url=https://books.google.com/books?id=YTeY9ZEfNccC&pg=PA486 |date=4 February 2013 |publisher=John Wiley & Sons |isbn=978-3-527-64565-7 |pages=486– |access-date=20 May 2018 |archive-date=12 January 2023 |archive-url=https://web.archive.org/web/20230112174738/https://books.google.com/books?id=YTeY9ZEfNccC&pg=PA486 |url-status=live }}</ref> | duration_of_action = | excretion = <!-- Identifiers --> | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 129453-61-8 | CAS_supplemental = | PubChem = 104741 | IUPHAR_ligand = 1015 | DrugBank_Ref = {{drugbankcite|changed|drugbank}} | DrugBank = DB00947 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = 94553 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 22X328QOC4 | KEGG_Ref = {{keggcite|changed|kegg}} | KEGG = D01161 | ChEBI_Ref = {{ebicite|changed|EBI}} | ChEBI = 31638 | ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL = 1358 | NIAID_ChemDB = | PDB_ligand = | synonyms = ICI-182780; ZD-182780; ZD-9238; 7α-[9-[(4,4,5,5,5-Pentafluoropentyl)-sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17β-diol <!-- Chemical and physical data --> | IUPAC_name = (7''R'',8''R'',9''S'',13''S'',14''S'',17''S'')-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[''a'']phenanthrene-3,17-diol | C=32 | H=47 | F=5 | O=3 | S=1 | SMILES = C[C@]12CC[C@@H]3c4ccc(O)cc4CC(CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O | StdInChI = 1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1 | StdInChI_comment = | StdInChIKey = VWUXBMIQPBEWFH-WCCTWKNTSA-N | density = | density_notes = | melting_point = | melting_high = | melting_notes = | boiling_point = | boiling_notes = | solubility = | sol_units = | specific_rotation = }} '''Fulvestrant''', sold under the brand name '''Faslodex''' among others, is an [[Antiestrogen|antiestrogenic]] [[medication]] used to treat hormone receptor (HR)-positive metastatic [[breast cancer]] in [[postmenopausal]] women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with [[abemaciclib]] or [[palbociclib]] in women with disease progression after endocrine therapy.<ref name="Faslodex FDA label" /> It is given by [[intramuscular injection|injection into a muscle]].<ref name="Cochrane2016">{{cite journal | vauthors = Lee CI, Goodwin A, Wilcken N | title = Fulvestrant for hormone-sensitive metastatic breast cancer | journal = The Cochrane Database of Systematic Reviews | volume = 1 | pages = CD011093 | date = January 2017 | issue = 1 | pmid = 28043088 | pmc = 6464820 | doi = 10.1002/14651858.CD011093.pub2 }}</ref> Fulvestrant is a [[selective estrogen receptor degrader]] (SERD) and was first-in-class to be approved.<ref name=NRDD2016>{{cite journal | vauthors = Lai AC, Crews CM | title = Induced protein degradation: an emerging drug discovery paradigm | journal = Nature Reviews. Drug Discovery | volume = 16 | issue = 2 | pages = 101–114 | date = February 2017 | pmid = 27885283 | pmc = 5684876 | doi = 10.1038/nrd.2016.211 }}</ref> It works by binding to the [[estrogen receptor]] and destabilizing it, causing the cell's normal [[protein degradation]] processes to destroy it.<ref name=NRDD2016/> Fulvestrant was approved for medical use in the United States in 2002.<ref name=AHFS2017>{{cite web|title=Fulvestrant|url=https://www.drugs.com/monograph/fulvestrant.html|publisher=The American Society of Health-System Pharmacists|access-date=8 January 2017|archive-date=2 February 2017|archive-url=https://web.archive.org/web/20170202013913/https://www.drugs.com/monograph/fulvestrant.html|url-status=live}}</ref> ==Medical uses== ===Breast cancer=== Fulvestrant is used for the treatment of hormone receptor positive metastatic breast cancer or locally advanced unresectable disease in postmenopausal women; it is given by injection.<ref name="Cochrane2016"/> A 2017 Cochrane review found it is as safe and effective as first line or second line endocrine therapy.<ref name=Cochrane2016/> It is also used to treat ER-positive, HER2-negative advanced or metastatic breast cancer in combination with [[abemaciclib]] or [[palbociclib]] in women with disease progression after first-line endocrine therapy.<ref name="Faslodex FDA label" /> Due to the medication's having a chemical structure similar to that of [[estrogen]], it can interact with [[immunoassay]]s for blood [[estradiol]] concentrations and show falsely elevated results.<ref name=HMGUK>{{cite web|title=Estradiol immunoassays – interference from the drug fulvestrant (Faslodex®) may cause falsely elevated estradiol results Medical safety alert - GOV.UK|url=https://www.gov.uk/drug-device-alerts/-estradiol-immunoassays-interference-from-the-drug-fulvestrant-faslodex-may-cause-falsely-elevated-estradiol-results|publisher=UK Medicines and Healthcare products Regulatory Agency|language=en|date=24 March 2016|access-date=2 May 2016|archive-date=19 July 2017|archive-url=https://web.archive.org/web/20170719083729/https://www.gov.uk/drug-device-alerts/-estradiol-immunoassays-interference-from-the-drug-fulvestrant-faslodex-may-cause-falsely-elevated-estradiol-results|url-status=dead}}</ref><ref name="pmid30679781">{{cite journal | vauthors = Owen LJ, Monaghan PJ, Armstrong A, Keevil BG, Higham C, Salih Z, Howell S | title = Oestradiol measurement during fulvestrant treatment for breast cancer | journal = Br J Cancer | volume = 120 | issue = 4 | pages = 404–406 | date = February 2019 | pmid = 30679781 | pmc = 6461991 | doi = 10.1038/s41416-019-0378-9 | url = }}</ref><ref name="pmid31927211">{{cite journal | vauthors = Samuel E, Chiang C, Jennens R, Faulkner D, Francis PA | title = Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer | journal = Eur J Cancer | volume = 126 | issue = | pages = 104–105 | date = February 2020 | pmid = 31927211 | doi = 10.1016/j.ejca.2019.10.015 | s2cid = 210166996 | url = }}</ref> This can improperly lead to discontinuing the treatment.<ref name=HMGUK/> ===Early puberty=== Fulvestrant has been used in the treatment of [[peripheral precocious puberty]] in girls with [[McCune–Albright syndrome]].<ref name="Fuqua2013">{{cite journal | vauthors = Fuqua JS | title = Treatment and outcomes of precocious puberty: an update | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 98 | issue = 6 | pages = 2198–207 | date = June 2013 | pmid = 23515450 | doi = 10.1210/jc.2013-1024 | doi-access = free }}</ref><ref name="Zacharin2019">{{cite book | vauthors = Zacharin M | title = Pediatric Pharmacotherapy | chapter = Disorders of Puberty: Pharmacotherapeutic Strategies for Management | series = Handbook of Experimental Pharmacology | date = May 2019 | volume = 261 | pages = 507–538 | publisher = Springer | pmid = 31144045 | doi = 10.1007/164_2019_208 | isbn = 978-3-030-50493-9 | s2cid = 169040406 }}</ref><ref name="SimsGarnett2012">{{cite journal | vauthors = Sims EK, Garnett S, Guzman F, Paris F, Sultan C, Eugster EA | title = Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome | journal = International Journal of Pediatric Endocrinology | volume = 2012 | issue = 1 | pages = 26 | date = September 2012 | pmid = 22999294 | pmc = 3488024 | doi = 10.1186/1687-9856-2012-26 | doi-access = free }}</ref> ===Available forms=== Fulvestrant is provided in a [[castor oil]] [[oil solution|solution]] also containing [[Alcohol (chemistry)|alcohol]], [[benzyl alcohol]], and [[benzyl benzoate]].<ref name="Faslodex FDA label" /> It is supplied at a concentration of 250 mg/5 mL.<ref name="Faslodex FDA label" /> ==Contraindications== Fulvestrant should not be used in women with [[kidney failure]] or who are [[pregnancy|pregnant]].<ref name="Faslodex FDA label" /><ref name=UKlabel2016>{{cite web|title=Faslodex 250 mg solution for injection - Summary of Product Characteristics|url=https://www.medicines.org.uk/emc/medicine/14381|publisher=UK Electronic Medicines Compendium|date=21 July 2016|access-date=25 January 2017|archive-date=10 October 2021|archive-url=https://web.archive.org/web/20211010195002/https://www.medicines.org.uk/emc/medicine/14381|url-status=live}}</ref> ==Side effects== Very common (occurring in more than 10% of people) adverse effects include nausea, injection site reactions, weakness, and [[elevated transaminases]]. Common (between 1% and 10%) adverse effects include urinary tract infections, hypersensitivity reactions, loss of appetite, headache, [[Venous thrombosis|blood clots in veins]], hot flushes, vomiting, diarrhea, elevated [[bilirubin]], rashes, and back pain.<ref name=UKlabel2016/> In a large clinical trial, the incidence of [[venous thromboembolism]] (VTE) with fulvestrant was 0.9%.<ref name="Faslodex FDA label" /> ==Pharmacology== ===Pharmacodynamics=== Fulvestrant is an [[antiestrogen]] which acts as an [[receptor antagonist|antagonist]] of the [[estrogen receptor]] (ER) and additionally as a [[selective estrogen receptor degrader]] (SERD).<ref name=NRDD2016/> It works by binding to the estrogen receptor and making it more [[hydrophobic]], which makes the receptor unstable and misfold, which in turn leads normal processes inside the cell to degrade it.<ref name=NRDD2016/> In addition to its antiestrogenic activity, fulvestrant is an [[agonist]] of the [[G protein-coupled estrogen receptor]] (GPER), albeit with relatively low affinity (10–100 nM, relative to 3–6 nM for estradiol).<ref name="pmid26023144">{{cite journal | vauthors = Prossnitz ER, Arterburn JB | title = International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators | journal = Pharmacol. Rev. | volume = 67 | issue = 3 | pages = 505–40 | date = July 2015 | pmid = 26023144 | pmc = 4485017 | doi = 10.1124/pr.114.009712 }}</ref><ref name="pmid15539556">{{cite journal | vauthors = Thomas P, Pang Y, Filardo EJ, Dong J | title = Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells | journal = Endocrinology | volume = 146 | issue = 2 | pages = 624–32 | date = February 2005 | pmid = 15539556 | doi = 10.1210/en.2004-1064 | doi-access = free }}</ref><ref name="pmid21844907">{{cite journal | vauthors = Prossnitz ER, Barton M | title = The G-protein-coupled estrogen receptor GPER in health and disease | journal = Nat Rev Endocrinol | volume = 7 | issue = 12 | pages = 715–26 | date = August 2011 | pmid = 21844907 | pmc = 3474542 | doi = 10.1038/nrendo.2011.122 }}</ref><ref name="pmid24530924">{{cite journal | vauthors = Prossnitz ER, Barton M | title = Estrogen biology: new insights into GPER function and clinical opportunities | journal = Mol. Cell. Endocrinol. | volume = 389 | issue = 1–2 | pages = 71–83 | date = May 2014 | pmid = 24530924 | pmc = 4040308 | doi = 10.1016/j.mce.2014.02.002 }}</ref><ref name="pmid22521564">{{cite journal | vauthors = Barton M | title = Position paper: The membrane estrogen receptor GPER--Clues and questions | journal = Steroids | volume = 77 | issue = 10 | pages = 935–42 | date = August 2012 | pmid = 22521564 | doi = 10.1016/j.steroids.2012.04.001 | s2cid = 35909008 | doi-access = free }}</ref> ===Pharmacokinetics=== Fulvestrant after an intramuscular injection is slowly absorbed and maximal levels (Cmax) are reached after 5 days on average with a range of 2 to 19 days.<ref name="pmid15094758">{{cite journal | vauthors = Robertson JF, Harrison M | title = Fulvestrant: pharmacokinetics and pharmacology | journal = Br J Cancer | volume = 90 | pages = S7–10 | date = March 2004 | issue = Suppl 1 | pmid = 15094758 | pmc = 2750771 | doi = 10.1038/sj.bjc.6601630 }}</ref> The [[elimination half-life]] of fulvestrant with intramuscular injection is 40 to 50 days.<ref name="pmid21319872" /><ref name="Faslodex FDA label" /> This is 40 times longer than the half-life of fulvestrant by [[intravenous injection]], indicating that its long half-life with intramuscular injection is due to slow absorption from the injection site.<ref name="pmid15094758" /> Levels of fulvestrant with 500 mg/month by intramuscular injection (and a single additional 500 mg [[loading dose]] on day 15 of therapy) in postmenopausal women with advanced breast cancer were 25.1 ng/mL (25,100 pg/mL) at [[Cmax (pharmacology)|peak]] and 28.0 ng/mL (28,000 pg/mL) at [[Cmin (pharmacology)|trough]] with a single dose and 28.0 ng/mL (28,000 pg/mL) at peak and 12.2 ng/mL (12,200 pg/mL) at trough after multiple doses at [[steady state (pharmacokinetics)|steady state]].<ref name="Faslodex FDA label" /> Fulvestrant does not cross the [[blood–brain barrier]] in animals and may not in humans as well.<ref name="pmid11900210">{{cite journal | vauthors = Robertson JF | title = ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data | journal = Br. J. Cancer | volume = 85 | pages = 11–4 | date = November 2001 | issue = Suppl 2 | pmid = 11900210 | pmc = 2375169 | doi = 10.1054/bjoc.2001.1982 | doi-broken-date = 1 November 2024 }}</ref><ref name="pmid16198055">{{cite journal | vauthors = Howell A, Abram P | title = Clinical development of fulvestrant ("Faslodex") | journal = Cancer Treat. Rev. | volume = 31 | pages = S3–9 | date = 2005 | issue = Suppl 2 | pmid = 16198055 | doi = 10.1016/j.ctrv.2005.08.010 }}</ref><ref name="pmid12113237">{{cite journal | vauthors = Bundred N, Howell A | title = Fulvestrant (Faslodex): current status in the therapy of breast cancer | journal = Expert Rev Anticancer Ther | volume = 2 | issue = 2 | pages = 151–60 | date = April 2002 | pmid = 12113237 | doi = 10.1586/14737140.2.2.151 | s2cid = 20294814 }}</ref> Accordingly, no effects of fulvestrant on [[brain]] function have been observed in [[preclinical research|preclinical]] or [[clinical research]].<ref name="pmid16198055" /><ref name="pmid12113237" /> Fulvestrant is highly (99%) [[plasma protein binding|bound to plasma proteins]].<ref name="pmid21319872">{{cite journal | vauthors = Croxtall JD, McKeage K | title = Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women | journal = Drugs | volume = 71 | issue = 3 | pages = 363–80 | date = February 2011 | pmid = 21319872 | doi = 10.2165/11204810-000000000-00000 | s2cid = 249870430 }}</ref><ref name="Faslodex FDA label" /> It is bound to [[very low density lipoprotein]], [[low density lipoprotein]], and [[high density lipoprotein]], but not to [[sex hormone-binding globulin]].<ref name="pmid21319872" /> Fulvestrant appears to be [[metabolism|metabolized]] along similar pathways as [[endogenous]] steroids; [[CYP3A4]] may be involved, but non-[[cytochrome P450]] routes appear to be more important. It does not inhibit any cytochrome P450 enzymes. Elimination is almost all via feces.<ref name=UKlabel2016/> Fulvestrant can form [[colloid]]al [[particle aggregation|aggregates]] at certain concentration ranges and this can limit its activity as well as produce [[bell shaped function|bell-shaped]] [[concentration–response curve]]s.<ref name="pmid30250495">{{cite journal | vauthors = Ganesh AN, Donders EN, Shoichet BK, Shoichet MS | title = Colloidal aggregation: from screening nuisance to formulation nuance | journal = Nano Today | volume = 19 | pages = 188–200 | date = April 2018 | pmid = 30250495 | pmc = 6150470 | doi = 10.1016/j.nantod.2018.02.011 }}</ref><ref name="pmid30840432">{{cite journal | vauthors = Ganesh AN, Aman A, Logie J, Barthel BL, Cogan P, Al-Awar R, Koch TH, Shoichet BK, Shoichet MS | title = Colloidal Drug Aggregate Stability in High Serum Conditions and Pharmacokinetic Consequence | journal = ACS Chem Biol | volume = 14 | issue = 4 | pages = 751–757 | date = April 2019 | pmid = 30840432 | pmc = 6474797 | doi = 10.1021/acschembio.9b00032 }}</ref><ref name="pmid24397822">{{cite journal | vauthors = Owen SC, Doak AK, Ganesh AN, Nedyalkova L, McLaughlin CK, Shoichet BK, Shoichet MS | title = Colloidal drug formulations can explain "bell-shaped" concentration-response curves | journal = ACS Chem Biol | volume = 9 | issue = 3 | pages = 777–84 | date = March 2014 | pmid = 24397822 | pmc = 3985758 | doi = 10.1021/cb4007584 }}</ref> ==Chemistry== Fulvestrant, also known as 7α-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estradiol, is a [[synthetic compound|synthetic]] [[estrane]] [[steroid]] and a [[chemical derivative|derivative]] of [[estradiol (medication)|estradiol]]. An [[alkyl]]-[[sulfinyl]] moiety was added to the endogenous estrogen receptor ligand.<ref name=NRDD2016/> It was discovered through rational drug design, but was selected for further development via [[phenotypic screening]].<ref>{{cite journal | vauthors = Moffat JG, Rudolph J, Bailey D | title = Phenotypic screening in cancer drug discovery - past, present and future | journal = Nature Reviews. Drug Discovery | volume = 13 | issue = 8 | pages = 588–602 | date = August 2014 | pmid = 25033736 | doi = 10.1038/nrd4366 | s2cid = 5964541 }}</ref> ==History== Fulvestrant was the first [[selective estrogen receptor degrader]] to be approved.<ref name=NRDD2016/> It was approved in the United States in 2002<ref name="Faslodex FDA label" /> and in the European Union in 2004.<ref name=UKlabel2016/> ==Society and culture== ===NICE evaluation=== The U.K. [[National Institute for Health and Clinical Excellence]] (NICE) said in 2011 that it found no evidence Faslodex was significantly better than existing treatments, so its widespread use would not be a good use of resources for the country's [[National Health Service (England)|National Health Service]]. The first month's treatment of Faslodex, which starts with a loading dose, costs £1,044.82 ($1,666), and subsequent treatments cost £522.41 a month.{{citation needed|date=May 2016}} In the 12 months ending June 2015, the UK price (excluding VAT) of a month's supply of [[anastrozole]] (Arimidex), which is off patent, cost 89 pence/day, and [[letrozole]] (Femara) cost £1.40/day.<ref>[https://www.gov.uk/government/publications/drugs-and-pharmaceutical-electronic-market-information-emit UK Department of Health Commercial Medicines Unit Electronic Medicines Information Tool] {{Webarchive|url=https://web.archive.org/web/20210817203140/https://www.gov.uk/government/publications/drugs-and-pharmaceutical-electronic-market-information-emit |date=17 August 2021 }}, London, 2015</ref><ref>[http://www.thepharmaletter.com/file/108724/uks-nice-says-no-to-astrazeneca-breast-cancer-drug-faslodex.html UK’s NICE says no to AstraZeneca breast cancer drug Faslodex] {{Webarchive|url=https://web.archive.org/web/20120426184813/http://www.thepharmaletter.com/file/108724/uks-nice-says-no-to-astrazeneca-breast-cancer-drug-faslodex.html |date=26 April 2012 }}, The Pharma Letter, 10 November 2011</ref><ref>[http://guidance.nice.org.uk/TA/Wave23/15 National Institute for Health and Clinical Excellence Guidance] {{Webarchive|url=https://web.archive.org/web/20110403012825/http://guidance.nice.org.uk/TA/Wave23/15 |date=3 April 2011 }} Breast cancer (metastatic) - fulvestrant</ref> ===Patent extension=== The original patent for Faslodex expired in October 2004. Drugs subject to pre-marketing regulatory review are eligible for patent extension, and for this reason AstraZeneca got an extension of the patent to December 2011.<ref>[http://www.uspto.gov/patents/resources/terms/156.jsp Patent Term Extensions] {{Webarchive|url=https://web.archive.org/web/20150108091004/http://www.uspto.gov/patents/resources/terms/156.jsp |date=8 January 2015 }} The United States Patent and Trademark Office.</ref><ref>[http://www.federalregister.gov/articles/2003/04/17/03-9536/determination-of-regulatory-review-period-for-purposes-of-patent-extension-faslodex Determination of Regulatory Review Period for Purposes of Patent Extension; FASLODEX] {{Webarchive|url=https://web.archive.org/web/20211101234940/https://www.federalregister.gov/documents/2003/04/17/03-9536/determination-of-regulatory-review-period-for-purposes-of-patent-extension-faslodex |date=1 November 2021 }} A Notice by the Food and Drug Administration on 17 April 2003</ref> AstraZeneca has filed later patents. A generic version of Faslodex has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity.<ref>[https://www.drugs.com/availability/generic-faslodex.html Generic Faslodex Availability] {{Webarchive|url=https://web.archive.org/web/20170731071226/https://www.drugs.com/availability/generic-faslodex.html |date=31 July 2017 }}, Drugs.COM</ref> A later patent for Faslodex expires in January 2021.<ref>[https://books.google.com/books?id=zVQMp4KJyeEC&dq=faslodex+patent+expiration&pg=PA199 Pink Ribbon Blues: How Breast Cancer Culture Undermines Women's Health] {{Webarchive|url=https://web.archive.org/web/20230919015930/https://books.google.com/books?id=zVQMp4KJyeEC&dq=faslodex+patent+expiration&pg=PA199 |date=19 September 2023 }} By Gayle A. Sulik, Oxford University Press (Oct. 2010)</ref> Atossa Genetics has a patent for the administration of fulvestrant into the breast via a microcatheter invented by [[Susan Love]].<ref>{{cite patent | country = US | number = 6638727 | status = granted | gdate = 28 October 2003 | title = Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer | inventor = Hung DT, Love S | assign1 = Cytyc Health Corp }}</ref> ==Research== Fulvestrant was studied in [[endometrial cancer]] but results were not promising and as of 2016 development for this use was abandoned.<ref>{{cite journal | vauthors = Battista MJ, Schmidt M | title = Fulvestrant for the treatment of endometrial cancer | journal = Expert Opinion on Investigational Drugs | volume = 25 | issue = 4 | pages = 475–83 | date = 2016 | pmid = 26882357 | doi = 10.1517/13543784.2016.1154532 | s2cid = 207477738 }}</ref> Because fulvestrant cannot be given orally, efforts have been made to develop [[Selective estrogen receptor degrader|SERD]] drugs that can be taken by mouth, including [[brilanestrant]] and [[elacestrant]].<ref name=NRDD2016/> The clinical success of fulvestrant also led to efforts to discover and develop a parallel drug class of [[selective androgen receptor degrader]]s (SARDs).<ref name=NRDD2016/> [[ZB716]], or fulvestrant-3-boronic acid, is an [[oral administration|oral]] [[prodrug]] of fulvestrant which is under development.<ref name="AhmadMathew2020">Ahmad, I., Mathew, S., & Rahman, S. (2020). Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer. RSC Medicinal Chemistry, 11(4), 438–454. https://doi.org/10.1039/C9MD00570F</ref><ref name="pmid27529700">{{cite journal | vauthors = Liu J, Zheng S, Akerstrom VL, Yuan C, Ma Y, Zhong Q, Zhang C, Zhang Q, Guo S, Ma P, Skripnikova EV, Bratton MR, Pannuti A, Miele L, Wiese TE, Wang G | title = Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD) | journal = J. Med. Chem. | volume = 59 | issue = 17 | pages = 8134–40 | year = 2016 | pmid = 27529700 | doi = 10.1021/acs.jmedchem.6b00753 | pmc = 5499704 }}</ref><ref>{{Cite web |url=https://www.clinicaltrials.gov/ct2/show/NCT04669587?term=NCT04669587&draw=2&rank=1 |title=ClinicalTrials.gov: NCT04669587 |access-date=4 January 2021 |archive-date=1 November 2021 |archive-url=https://web.archive.org/web/20211101235031/https://www.clinicaltrials.gov/ct2/show/NCT04669587?term=NCT04669587&draw=2&rank=1 |url-status=live }}</ref> == References == {{Reflist}} {{Estrogens and antiestrogens}} {{Estrogen receptor modulators}} {{AstraZeneca}} {{Portal bar | Medicine}} {{Authority control}} [[Category:Antiestrogens]] [[Category:Drugs developed by AstraZeneca]] [[Category:Estranes]] [[Category:GPER agonists]] [[Category:Hormonal antineoplastic drugs]] [[Category:Organofluorides]] [[Category:Peripherally selective drugs]] [[Category:Selective estrogen receptor degraders]]
Fulvestrant
に戻る。
ナビゲーション メニュー
個人用ツール
ログイン
名前空間
ページ
日本語
表示
閲覧
履歴表示
その他
検索
案内
索引
脳科学辞典について
最近完成した項目
編集履歴
執筆にあたって
引用の仕方
著作権について
免責事項
問い合わせ
各学会編集のオンライン用語辞典
About us (in English)
Twitter (BrainScienceBot)
ツール
リンク元
関連ページの更新状況
特別ページ
ページ情報
他のプロジェクト